Clinical Report: Decreased Levels of DPP9 Enhance Sensitivity of Experimental Breast Tumors to Combined Irradiation and Olaparib Therapy
Overview
Reduced expression of dipeptidyl peptidase 9 (DPP9) in triple-negative breast cancer (TNBC) enhances sensitivity to combined irradiation and Olaparib therapy. This study utilized a mouse model to demonstrate the effects of DPP9 deficiency on treatment response.
Background
Triple-negative breast cancer (TNBC) is known for its aggressive nature and poor prognosis due to limited targeted therapies. DPP9 has been associated with tumor growth and metastasis in breast cancer, with lower levels correlating with worse patient outcomes.
Data Highlights
No numerical data or trial data provided in the source material.
Key Findings
DPP9 deficiency in TNBC models resulted in increased tumor weight and lung metastasis.
Upon irradiation, DPP9-deficient tumors exhibited faster regrowth compared to controls.
Combined treatment with irradiation and Olaparib further reduced tumor growth in DPP9-deficient tumors.
Metastasis formation showed mixed outcomes in DPP9-deficient tumors after treatment.
DPP9 is implicated in the proteolytic cleavage of BRCA2, affecting DNA repair mechanisms.
Clinical Implications
Clinicians should consider DPP9 expression when designing therapeutic strategies involving irradiation and PARP inhibitors like Olaparib.
Conclusion
This study demonstrates that reduced DPP9 levels enhance sensitivity to combined therapies in TNBC.
